Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Tamara Lesperance"'
Autor:
Dinesh Khanna, Daniel E. Furst, Justin W. Li, Qian Meng, Yuan Yuan, Tamara Lesperance, Kenyatta Peoples, Farah Ali, Brian LaMoreaux, Stephanie D. Taylor
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 12, Pp 677-684 (2023)
Objective To describe the health care resource use (HCRU) and costs of patients with systemic sclerosis (SSc) prior to and after diagnosis. Methods This retrospective study used a claims data set (Merative MarketScan; 2015‐2019). Eligible patients
Externí odkaz:
https://doaj.org/article/b6f63ba73e5744dbbb31b7a2aef88f44
Autor:
Dimitrios A. Pappas, Ying Shan, Tamara Lesperance, Greg Kricorian, Elaine Karis, Sabrina Rebello, Winnie Hua, Neil A. Accortt, Scott Stryker
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 10, Pp 588-594 (2020)
Objective The purpose of this study was to evaluate maintenance of remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) who achieved remission/LDA with etanercept (ETN) plus a conventional synthetic disease‐modifying anti
Externí odkaz:
https://doaj.org/article/df74e938f6c74b0ebcf00d1564feaef8
Autor:
Scott Stryker, Ying Shan, Sabrina Rebello, Greg Kricorian, Elaine Karis, Neil A. Accortt, Tamara Lesperance, Winnie Hua, Dimitrios A. Pappas
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 10, Pp 588-594 (2020)
ACR Open Rheumatology
ACR Open Rheumatology
Objective The purpose of this study was to evaluate maintenance of remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) who achieved remission/LDA with etanercept (ETN) plus a conventional synthetic disease-modifying antirh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad3922e960cbfee59d3d35141e7332dc
https://doi.org/10.1002/acr2.11168
https://doi.org/10.1002/acr2.11168
Autor:
Dimitrios A. Pappas, Scott Stryker, Elaine Karis, Greg Kricorian, Tamara Lesperance, Heather J. Litman, Sabrina Rebello, Neil A. Accortt, Winnie Hua
Publikováno v:
Rheumatology International
Biological disease-modifying antirheumatic drugs (bDMARDs) monotherapy may enhance adherence and decrease adverse events compared to combination therapy with conventional synthetic DMARDs (csDMARDs); however, persistence with bDMARD monotherapy has n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abb0ca3e82c0a8061b69cb5c0da0d630
https://doi.org/10.1007/s00296-020-04667-5
https://doi.org/10.1007/s00296-020-04667-5
Publikováno v:
Arthritis Care & Research
Objective To examine disease-modifying antirheumatic drug (DMARD) treatments and estimate the risk of a subsequent cardiovascular (CV) event following an initial CV event in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or psori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8292d7fe3be39e01e1924bae48b196e3
http://europepmc.org/articles/PMC6252288
http://europepmc.org/articles/PMC6252288
Impact of Sustained Remission on the Risk of Serious Infection in Patients With Rheumatoid Arthritis
Autor:
Mona Trivedi, Sabrina Rebello, Youfu Li, Tamara Lesperance, Jeffrey R. Curtis, Neil A. Accortt, Mei Liu
Publikováno v:
Arthritis Care & Research
Objective This retrospective analysis examined how sustained remission impacted risk of serious infections in patients with rheumatoid arthritis (RA) enrolled in a clinical registry. Methods Inclusion criteria included RA diagnosis, ≥18 years old,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72900ea8382080bd75f3e1dda6eb4c3c
https://doi.org/10.1002/acr.23426
https://doi.org/10.1002/acr.23426
Publikováno v:
Arthritis Care & Research. 69:1510-1518
Objective To estimate prevalence and incidence of cardiovascular (CV) risk factors of hypertension, diabetes mellitus, hyperlipidemia, and obesity in patients with rheumatoid arthritis (RA), psoriasis, or psoriatic arthritis (PsA). Methods Patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf2e0046195b9ea921d15c873a5f0243
https://doi.org/10.1002/acr.23171
https://doi.org/10.1002/acr.23171
Autor:
Tamara Lesperance, Neil A. Accortt, Dimitrios A. Pappas, Sabrina Rebello, Gregory Kricorian, Elaine Karis, Winnie Hua, Heather J. Litman
Publikováno v:
FRIDAY, 15 JUNE 2018.
Background Combination therapy with TNFis and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) is standard for moderate to severe RA. Objectives To estimate persistence with etanercept (ETN) or other TNFi monotherapy among RA p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::391a8738d14dd394bfd5e7ef71e7da59
https://doi.org/10.1136/annrheumdis-2018-eular.1509
https://doi.org/10.1136/annrheumdis-2018-eular.1509
Publikováno v:
Oral Presentations.
Background Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, a gap in knowledge exists regarding detailed information on changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c6fe0e34d9c904d95d8a3fe51ca5172
https://doi.org/10.1136/annrheumdis-2017-eular.2324
https://doi.org/10.1136/annrheumdis-2017-eular.2324
Autor:
Tamara Lesperance, Philip J. Mease, Mei Liu, David H. Collier, Sabrina Deveikis, Neil A. Accortt, Marc Mason
Publikováno v:
The Journal of rheumatology. 44(2)
Objective.Treatment options for psoriatic arthritis (PsA) have increased and improved in the past decade; treatment patterns in PsA remain poorly understood. Understanding current practices would aid in treatment management of patients with PsA.Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdc362834889123768ba28e919c686bc
https://pubmed.ncbi.nlm.nih.gov/28089969
https://pubmed.ncbi.nlm.nih.gov/28089969